Cartherics gets $300k grant to advance Cell and Gene Therapy development, ET HealthWorld
Melbourne: An immune cell therapies for cancer and other diseases developer, Cartherics Pty Ltd announced that it has been awarded a US$300K G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.
This grant will be used to purchase equipment and reagents to support Cartherics’ R&D and manufacturing programs, specifically platform assessment, method development and upscaling CTH-401 for clinical trials, the biotech company said in a press statement.
Utilising the G-Rex system early in product development will also benefit Cartherics’ other drug candidates by helping to streamline the development process, it added.
“Investing in our own manufacturing capability allows us to be more nimble in product development time, save money and further utilise the expertise of our scientists who have developed our manufacturing processes rather than being required to tech transfer capabilities with limited long term knowledge gain,” said Dr Damien Zanker, Head of Clinical Manufacturing, Cartherics’.
Visit: Valley Vision News
